For more updates follow Grant Thornton Bharat on WhatsApp
The evolving macroeconomic landscape and dynamic business environment continually present challenges to large and expanding businesses, especially those with international operations.
Grant Thornton offers a solution with our Dealtracker publication, providing comprehensive deal insights at your fingertips. This publication delivers highlights, sector updates, and in-depth analyses of current opportunities and challenges in the industry.
With nearly two decades of active tracking in PE investment and M&A deal activities, our flagship publication, Dealtracker, remains a reliable source. We emphasise that both these activities will play a pivotal role as the Indian economy aims to regain its high growth trajectory. To achieve this, India Inc. must intensify its focus on both private equity investments, and mergers and acquisitions.
The report features extensive data on VC/PE investments and M&A deal activities, offering insights into industry growth across sectors and companies of various sizes. Our coverage is comprehensive, capturing deals within the Indian territory and providing timely reports that offer an overview of deal sentiment in India.
Our suite of coverage includes:
The Monthly Dealtracker January 2026 review captures India’s deal environment with data on M&A, private equity, capital market values, sector highlights and macro trends shaping investment momentum and strategic transactions at the start of 2026.
Annual Dealtracker 2025 analyses India’s record deal activity, including M&A, PE/VC, and sector trends. The report highlights macro resilience, policy support, and deal momentum into 2026.
November 2025 marked a significant milestone for India’s deal environment, reflecting strong momentum across mergers and acquisitions and private equity transactions.
India’s deal activity in October 2025 reflected strong momentum across mergers, acquisitions, private equity, and public listings.
The Pharma and Healthcare Dealtracker Q3 2025 by Grant Thornton Bharat analyses India’s evolving life sciences ecosystem, highlighting a 28% surge in deal volumes and a 166% rise in values. The report explores M&A, private equity, and capital market activity shaping pharma, healthcare, and biotech growth.
The Q3 2025 edition of the Technology Dealtracker outlines this directional change, highlighting strategic movements across private equity and M&A, especially in mid-market and outbound segments.
According to the Grant Thornton Bharat Dealtracker, excluding IPOs and QIPs, August 2024 deal activity witnessed a significant surge, with a total of 179 deals, amounting to USD 8.7 billion, marking a 63% increase in value compared to July.
According to the Grant Thornton Bharat Dealtracker, Q2 2024, Indian dealmaking witnessed an overall 501 deals, valued at USD 21.4 billion.
Grant Thornton Bharat acts as exclusive advisor to Biorad Medisys for its fundraise of up to INR 400 Crore from Kotak Strategic Situations India Fund II